Fig. 4.
Validation of small molecule inhibitors affecting HIV-1 infection. Significant hits identified from preliminary analysis were validated on a minimum three healthy donors. Compounds having previous effects on HIV-1 infection including nucleoside analogs were excluded from downstream experiments. All conditions were performed in triplicate. Error bars represent SEM (ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001)